Evidence map›Paper›PMID 20142002›Full record

ArticleAnnals of vascular surgery2010

Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline.

Vikram Sood, Cathy Luke, Erin Miller, Mayo Mitsuya, Gilbert R Upchurch, Thomas W Wakefield, Dan D Myers, Peter K Henke

Open access · greenAbstract readComparative Study
In one paragraph

Article in Annals of vascular surgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Insights from experimental post-thrombotic syndrome and potential for novel therapies.Translational research : the journal of laboratory and clinical medicine · 2020
    Review
  4. Novel microspheres reduce the formation of deep venous thrombosis and repair the vascular wall in a rat model.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2017
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Vikram SoodJobst Vascular Surgery Laboratory, Section of Vascular Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Cathy Luke
Erin Miller
Mayo Mitsuya
Gilbert R Upchurch
Thomas W Wakefield
Dan D Myers
Peter K Henke
University of Michigan–Ann Arbor · US

Funding

Vein wall remodeling after DVT is matrix metalloproteinase dependentR01HL083918 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HENKE, PETER K · 2006 to 2009
$1.4M
NHLBI NIH HHS HL083918NHLBI NIH HHS R01 HL083918
6 · The paper itself

Abstract

backgroundVenous thrombus resolution sets up an early intense inflammatory reaction, from which vein wall damage results. Tissue response to injury includes matrix metalloproteinase (MMP) activation and extracellular matrix protein turnover. This study sought to determine the effect of exogenous MMP inhibition and its potential attenuation of early vein wall injury.

methodsRats received treatment beginning 24 hr after a stasis venous thrombosis by near occlusive ligation and until harvest at day 7. Three groups were evaluated: (1) vehicle saline controls (NaCl), (2) low molecular weight heparin (LMWH; Lovenox, 3 mg/kg daily SQ), and (3) doxycycline (DOXY, 30 mg/kg daily PO). Thrombus size (mg/mm), levels of tumor necrosis factor alpha (TNF alpha) and D-dimer by colorimetric assay, and monocytes counts by immunohistochemistry were assessed. Vein wall assessment included stiffness by tensiometry, interleukin 1beta (IL-1 beta protein levels by enzyme-linked immunosorbent assay, MMP2 and -9 by zymography, and histological analysis of intimal thickness (IT). Comparisons were by t-test to control. p < 0.05 was considered significant.

resultsThrombus sizes were similar at days 2 and 7 for all three groups, while thrombus TNFalpha was increased in 2-day LMWH- and DOXY-treated groups (NaCl = 1.0 +/- 0.8, LWMH = 9 +/- 3, DOXY = 27 +/- 5 pg/mg protein, n = 6-8, p < 0.05) and at 7 days in the DOXY group (NaCl = 3.0 +/- 2.5, DOXY = 23 +/- 4.2 pg/mg protein, n = 5, p < 0.05). Vein wall stiffness at 7 days was less with LMWH treatment, but not with DOXY, compared to controls (NaCl = 0.33 +/- 0.05, LMWH = 0.17 +/- 0.03, DOXY = 0.43 +/- 0.09 N/mm, n = 5-7, p < 0.05). Vessel-wall IL-1 beta was reduced only in the DOXY group at 7 days (NaCl = 26 +/- 3, LMWH = 38 +/- 17, DOXY = 6 +/- 3 pg/mg protein, n = 4-6, p < 0.05), as was the IT score versus controls (NaCl = 2.2 +/- 0.6, LMWH =1.7 +/- 0.3, DOXY = 0.8 +/- 0.20, n = 4-6, p < 0.05). Zymographic MMP9 activity was significantly reduced at 2 days in the LMWH and DOXY groups (NaCl = 85 +/- 24, LMWH = 23 +/- 7( *), DOXY = 13 +/- 5 U/mg protein, n = 6-8, p < 0.05). MMP2 zymographic activity, thrombus monocyte cell counts, and D-dimer activity were not significantly different across groups.

conclusionTreatment with LMWH or DOXY did not alter the size of deep vein thrombosis, mildly altered thrombus composition, and differentially affected vein wall injury, despite similar reductions in early MMP9 activity. Whether exogenous MMP inhibition affects long-term vein wall fibrosis will require further study.

Indexed as

AnimalsDisease Models, AnimalDoxycyclineElasticityEnoxaparinFibrin Fibrinogen Degradation ProductsFibrinolytic AgentsFibrosisInterleukin-1betaLigationMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsPlasminogen Activator Inhibitor 1Protease InhibitorsDoxycyclineEnoxaparinFibrin Fibrinogen Degradation Productsfibrin fragment DFibrinolytic AgentsInterleukin-1betaMatrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsMmp2 protein, ratPlasminogen Activator Inhibitor 1Protease InhibitorsTumor Necrosis Factor-alphaUrokinase-Type Plasminogen Activator

Identifiers

PMID20142002
PMCPMC2997482
OpenAlexW2054195365

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.